Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03360071 · ClinicalTrials.gov registry record · Phase 2
A Novel Biologic Therapy for Perennial Allergic Rhinitis
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03360071: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03360071 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03360071, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as a sub-cutaneously administered immunotherapy for the management of allergic rhinitis (perennial and seasonal).
Interventions
- DRUG Allergen Immunotherapy Extract
- DRUG Allergen Immunotherapy Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03360071
The ClinicalTrials.gov registry entry for NCT03360071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allergen Immunotherapy Extract is the first listed.
NCT03360071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03360071 about?
NCT03360071 is a clinical study titled "A Novel Biologic Therapy for Perennial Allergic Rhinitis". This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as a sub-cutaneously administered immunotherapy for the management of allergic rhinitis (perennial and seasonal).
What is the current status of trial NCT03360071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2016-12-19. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT03360071?
The interventions under investigation include: Allergen Immunotherapy Extract (DRUG), Allergen Immunotherapy Control (DRUG).
Who is sponsoring clinical trial NCT03360071?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.